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Abstract: 
The purpose of this study was to analyse the characteristics of arterial hypertension clinical course in patients 
with sleep disorders for optimization of preventive and curative interventions algorithms, blood pressure 
control, cardiovascular complications prevention, improvement of patients’ life quality. Materials and Methods: 
We examined 89 patients with arterial hypertension aged from 30 to 70 years. The arterial hypertension 
diagnosis was based on ESC Clinical Practice Guidelines – ESC/ESH Arterial Hypertension (Management of) 
(2018). We analysed the clinical, instrumental and laboratory status of patients with arterial hypertension. All 
data was evaluated with STATGRAPHICS 5.1, Microsoft Office Excel, Statistica 8.0. Results: the patients with 
arterial hypertension have expressed dissomnic and psychosomatic disorders which have significant negative 
influence on the arterial hypertension clinical course and the disease prognosis. Low urine melatonin level is 
associated with increased blood pressure, blood pressure variability, sleep disorders, psychosomatic disorders, 
and low life quality of patients with arterial hypertension. Prescription of melatonin in the patients with arterial 
hypertension with sleep disorders is reasonable to correct dissomnic and psychosomatic disorders, clinical 
symptoms load of arterial hypertension, improvement of disease prognosis and life quality of patients with 
arterial hypertension. 
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INTRODUCTION: 
Arterial hypertension is a current problem of modern 
medicine. First of all, arterial hypertension is 
widespread problem, which leads to permanent 
functional loss and social and economic losses [1]. 
Arterial hypertension is a main risk factor of 
cardiovascular accidents emergence (myocardial 
infarction, brain attack), which lead to population 
early disability and determine high mortality rate in 
the world. According to 2018 ESC/ESH Guidelines 
for the management of arterial hypertension the 
prevalence of AH is 43.4% [2]. At simplicity and 
availability of arterial hypertension treatment, only 
14.4% of men and 30.9% of women have effective 
blood pressure control [3]. However, in spite of high 
prevalence and significance of arterial hypertension, 
the etiology and pathogenetic mechanisms are not 
investigated to the end. 
 
Arterial hypertension is a multifactorial disease in 
which developing the difficult mechanisms of 
internal (genetic) and external factors interaction are 
based [3]. 
 
The combination of genetic predisposition to 
cardiovascular risk factors leads to development of 
arterial hypertension. The cardiovascular risk factors 
are psycho-emotional stress, tobacco smoking, 
abdominal alcohol-related diseases, abdominal 
obesity, hypodynamia, high dietary salt intake [4]. 
 
Now arterial hypertension is a disease which can be 
controlled. Even insignificant decrease of blood 
pressure reduces the risks of target organ disease. 
Meta-analysis of the randomized controlled studies 
devoted to studying of antihypertensive therapy 
efficiency showed, the risk of myocardial infarction 
developing decreases by 22.0% and stroke – by 
41.0% if systolic blood pressure decreases by 10 mm 
Hg. or diastolic blood pressure decreases by 5 mm 
Hg. 
 
S. Lewington and coauthor (2002) show, the effective 
treatment of arterial hypertension reduces the 
cardiovascular diseases mortality by 15.0-20.0% [5]. 
 
Today the sleep disorders are the current problem 
which is found in population. The sleep is one of 
modulators of different systems at normal also at 
pathology [6-7]. 
 
The sleep is the process which consists of 
consecutive functional conditions of a brain. It 
includes synchronized sleep and REM sleep (rapid 
eye movement in sleep). The normal sleep is an 
eight-hour sleep which consists of 4 or 6 undulation 
cycles by 90 minutes. The sleep significantly has an 
effect on vegetative nervous system, hemodynamic 
and a cardiovascular system. Sleep disorders lead to 
memory and attention impairment, performance 
decrement. Sleep disorders are associated with 
developing of frequent headaches, iracundity. The 
chronic stress, psychic tension, somatic diseases are 
triggers for sleep disorders or insomniya. On the one 
hand, the rare appealability, on the other hand, 
simplicity of this problem, lead to the fact that only 
tithe patients receive the treatment of sleep disorders 
[8]. 
 
Normal the blood pressure is much lower while 
sleeping in comparison with active waking. Circadian 
variance of blood pressure most likely are connected 
with the regulating pineal gland hormone influence – 
melatonin. Decrease in production of melatonin leads 
to inadequate lowering of blood pressure while 
sleeping in patients with arterial hypertension. 
Besides, pineal gland hormone an play an adaptogen 
role in patients with increased meteorological and 
geomagnetic communication [5,9]. 
 
The combination of standard arterial hypertension 
therapy with melatonin intake enables to 
normalization of sleep quality, decreasing of relation 
between weather factors, intensity of geomagnetic 
activity and blood pressure. It results in the expressed 
hypotensive effect of standard therapy and 
normalization of blood pressure [10]. 
 
At arterial hypertension there are single researches 
concerning melatonin influence on the disease 
clinical course, blood pressure control. And 
researches with the assessment of clinical parameters, 
psychological status, sleep quality and patients’ life 
quality in dependence on the melatonin level and its 
participation in blood pressure control were 
practically not conducted. 
 
In the present work, the goal has been set – to analyse 
the characteristics of arterial hypertension clinical 
course in patients with sleep disorders for 
optimization of preventive and curative interventions 
algorithms, blood pressure control, cardiovascular 
complications prevention, improvement of patients’ 
life quality. 
To achieve the goal, the following tasks were 
solved: 
1. To analyse the dissomnic and 
psychosomatic disorders in patients with 
arterial hypertension. 
2. To study the characteristics of arterial 
hypertension clinical course in patients 
with sleep disorders. 
3. To reveal communication between blood 
pressure level and sleep disorders, urine 
melatonin level. 
4. To study the characteristics of arterial 
hypertension clinical course depending on 
urine melatonin level. 
5. To define the major factors having an 
impact on dissomnic and psychosomatic 
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disorders in patients with arterial 
hypertension in dependence of urine 
melatonin level. 
 
MATERIALS AND METHODS: 
We examined 89 patients with arterial hypertension 
((42/47.2% women and 47/52.8% men) aged from 30 
to 70 years (mean age, 59.40±0.75 years). The 
arterial hypertension diagnosis was based on ESC 
Clinical Practice Guidelines – ESC/ESH Arterial 
Hypertension (Management of) (2018). 
 
The study was approved by the Ethics Committee of 
Voronezh State Medical University named after N.N. 
Burdenko. Written informed consent was obtained 
from each patient. 
 
A comprehensive clinical examination, functional 
and laboratory tests included the following 
procedures: 
 Assessment of arterial hypertension severity 
included the visits to the general practice doctor 
and the hospital admissions for the past 12 
months. 
 Quantity assessment of arterial hypertension 
symptoms (headache, vertigo, seeing spots, 
general weakness) by the 10-point Visual 
Analogue Scale. 
 Assessment of dissomnic disorders by 
Pittsburgh Sleep Quality Index (PSQI). 
 Assessment of psychosomatic disorders (anxiety 
level, depression level) by State-Trait Anxiety 
Inventory (STAI) and Zung Self-Rating 
Depression Scale. 
 Assessment of life quality by Short Form 
Medical Outcomes Study 36 (SF-36). 
 Functional tests: echocardiography (EchoCG), 
24-hour blood pressure monitoring. 
 Laboratory tests: clinical blood analysis, clinical 
urine analysis, biochemical blood analysis, urine 
melatonin level. 
 
All data was evaluated with STATGRAPHICS 5.1, 
Microsoft Office Excel, Statistica 8.0. Baseline 
characteristics were summarized as frequencies and 
percentages for categorical variables and as 
mean±SD for continuous variables. Student’s 
unpaired t-test was used to compare two groups for 
data with normal distribution. A probability value of 
P<0.05 was considered statistically significant. 
 
RESULTS AND DISCUSSION: 
We analysed the clinical, instrumental and laboratory 
status of patients with arterial hypertension. 
 
The number of visits to the general practice doctor 
was 2.39±0.07 per year, hospital admissions – 
0.60±0.06 per year. 
 
The subjective assessment of arterial hypertension 
symptoms, according to the 10-point Visual 
Analogue Scale, demonstrated, headache was 
4.60±0.09, vertigo was 3.19±0.09, seeing spots were 
2.50±0.07, general weakness was 6.15±0.11. 
 
According to EchoCG the left ventricular 
hypertrophy were revealed. Left ventricle posterior 
wall was 1.1±0.01 cm, interventricular septum 
thickness was 1.2±0.02 cm. 78/87.6% patients have 
not luxus heart, and 11/12.4% patients have luxus 
heart. Systolic left ventricular function was kept at all 
patients; left ventricular ejection fraction was 
56.39±0.59%. 
 
According to 24-hour blood pressure monitoring 
average daily blood pressure was 151±3.4/84±2.9 
mm Hg, average day-time blood pressure was 
157±2.8/89±3.1 mm Hg, and average night-time 
blood pressure was 140±2.5/78±2.9 mm Hg. There 
are 4 types of patients depending of systolic blood 
pressure night decrease: 2/2.3% patients were dipper, 
39/43.8% patients were non-dipper, 47/52.8% 
patients were night-dipper, and 1/1.1% patients was 
over-dipper. There are 4 types of patients depending 
of diastolic blood pressure night decrease: 3/3.3% 
patients were dipper, 42/47.2% patients were non-
dipper, 42/47.2% patients were night-dipper, and 
2/2.3% patients were over-dipper. 
 
According to clinical blood analysis, clinical urine 
analysis, biochemical blood analysis nothing 
abnormal detected. 
 
The assessment of serum lipid profile was revealed 
dyslipidemia. Total cholesterol was 6.09±0.09 mMol 
/L, low density lipoprotein cholesterol was 4.01±0.12 
mMol /L, high density lipoprotein cholesterol was 
0.88±0.03 mMol/L, and triglyceride was 2.05±0.08 
mMol/L. 
Urine melatonin level was 10.60±1.24 ng/ml. 
 
We analysed the dissomnic and psychosomatic 
disorders of patients with arterial hypertension. 
Assessment of dissomnic disorders was by Pittsburgh 
Sleep Quality Index (PSQI). PSQI was 7.44±0.20.  
 
The patients with arterial hypertension showed the 
various complaints connected with sleep disorders. 
They are fatigue when awakening after night sleep 
(75/84.3% patients), difficulty in falling asleep 
(60/67.4% patients), superficial sleep with night 
awakenings (58/65.2% patients), superficial sleep 
with a set of dreams (51/57.3% patients), 
sleeplessness more than 30 minutes (56/62.9% 
patients), night awakenings with headache complaints 
(37/41.5% patients), ghastly dreams (25/28.1% 
patients), daytime sleepiness (23/25.8% patients), 
daytime sleep (13/14.6% patients), rhythmical 
movement while sleeping (9/10.1% patients), sleep 
deficiency (5/5.6% patients) 
 
We analysed the arterial hypertension clinical course 
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and dissomnic disorders in patients of the general 
group. If the arterial hypertension degree, 
stratification risk of complications, systolic blood 
pressure, diastolic blood pressure are higher, disease 
is long-continued, then dissomnic disorders are 
significant more severity (p < 0.05). Also the 
irregularity of hypotensive therapy significantly 
influences on patients sleep quality (p < 0.05). 
 
Assessment of psychosomatic disorders was by State-
Trait Anxiety Inventory (STAI) and Zung Self-Rating 
Depression Scale.  
 
In the general group there are patients with high state 
anxiety (53/59.6%) and patients with high trait 
anxiety (49/55.1%). 36/40.5% patients were with 
medium state anxiety. 40/44.9% patients were with 
medium trait anxiety. There are not patients with low 
state and trait anxiety levels in the general group. 
State anxiety level was 44.63±0.66. Trait anxiety 
level was 44.17±0.66. 
 
In the general group there are patients without 
depression (18/20.2%). 41/46.1% patients have mild 
(neurotic) depression, 30/33.7% patients have 
masked depression. There are not patients with true 
depression in the general group. Depression level was 
55.29±0.94. 
 
We analysed the arterial hypertension clinical course 
and psychosomatic disorders in patients of the 
general group. If the arterial hypertension degree, 
stratification risk of complications, systolic blood 
pressure, diastolic blood pressure are higher, disease 
is long-continued, then psychosomatic disorders are 
significant more severity: state and trait anxiety, 
depression level are higher (p < 0.05). Also the 
irregularity of hypotensive therapy significantly 
influences on psychosomatic disorders 
expressiveness in patients of the general group (p < 
0.05). 
 
The life quality assessment by SF-36 revealed the 
low health status of patients with arterial 
hypertension. The lowest average values had 4 scales. 
Role-Physical Functioning (RP) was 41.07±1.71, 
Bodily Pain (BP) was 42.69±1.46, and Role 
Emotional (RE) was 40.49±1.46. 
 
We carried out the correlation analysis to identify the 
dependences and statistic relation between the studied 
characteristic.  
 
The data of correlation analysis confirmed the results 
of our research. The frequent visits to the general 
practice doctor, the frequent hospital admissions, the 
high arterial hypertension degree, high stratification 
risk of complications, long-continued disease, 
irregularity of hypotensive therapy, marked arterial 
hypertension symptoms, blood pressure variability, 
dyslipidemia, low urine melatonin level are 
correlated with more severity dissomnic and 
psychosomatic disorders (high PSQI, high state and 
trait anxiety levels, high depression level), low 
quality of life. 
 
We carried out the One-Way ANOVA to assess the 
influence of independent variable (factors) on the end 
result (sign). 
 
One-Way ANOVA was carried out to identify the 
influence of the behavioral performances (smoking, 
regularity of hypotensive therapy), dissomnic and 
psychosomatic disorders (PSQI, state and trait 
anxiety, depression), urine melatonin level on the 
arterial hypertension clinical course (arterial 
hypertension degree, visits to the general practice 
doctor, hospital admissions, stratification risk of 
complications, long-continued disease). 
 
According to One-Way ANOVA smoking, PSQI, 
state and trait anxiety, depression, urine melatonin 
level significant influence on arterial hypertension 
degree.  
 
The 3rd degree of arterial hypertension was 
diagnosed for the smoking patients significant more 
often (F=21.96; p=0.0000). 
 
In patients of the general group PSQI, state and trait 
anxiety level, depression level, urine melatonin level 
significant differed depending on arterial 
hypertension degree. 
 
At the 1st degree of arterial hypertension PSQI was 
4.8±0.20; at the 2nd degree of arterial hypertension 
PSQI was 6.86±1.19; at the 3rd degree of arterial 
hypertension PSQI was 9.03±0.40 (F=23.96; 
p=0.0000). 
 
At the 1st degree of arterial hypertension state 
anxiety level was 36.8±1.07; at the 2nd degree of 
arterial hypertension state anxiety level was 
42.45±0.86; at the 3rd degree of arterial hypertension 
state anxiety level was 49.18±0.53(F=23.80; 
p=0.0000).  
 
At the 1st degree of arterial hypertension trait anxiety 
level was 37.4±1.12; at the 2nd degree of arterial 
hypertension trait anxiety level was 41.57±0.79; at 
the 3rd degree of arterial hypertension trait anxiety 
level was 49.21±0.59 (F=30.70; p=0.0000). 
 
At the 1st degree of arterial hypertension depression 
level was 40.8±0.58; at the 2nd degree of arterial 
hypertension depression level was 51.22±0.88; at the 
3rd degree of arterial hypertension depression level 
was 63.79±0.77 (F=70.75; p=0.0000). 
 
At the 1st degree of arterial hypertension urine 
melatonin level was 31.89±1.21 ng/ml; at the 2nd 
degree of arterial hypertension urine melatonin level 
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was 11.48±1.19 ng/ml; at the 3rd degree of arterial 
hypertension urine melatonin level was 2.92±0.55 
ng/ml (F=49.07; p=0.0000). 
 
According to One-Way ANOVA PSQI, state and trait 
anxiety, depression have significant influence on 
visits to the general practice doctor.  
 
In patients of the general group PSQI, state and trait 
anxiety level, depression level significant differed 
depending on visits to the general practice doctor. 
 
At one visit a year PSQI was 6.12±0.61; at two visits 
a year PSQI was 6.93±0.28; at three visits a year 
PSQI was 8.23±0.39; at four visits a year PSQI was 
8.50±1.32 (F=3.97; p=0.0107). 
 
At one visit a year state anxiety level was 
37.12±0.97; at two visits a year state anxiety level 
was 41.97±0.44; at three visits a year state anxiety 
level was 49.26±0.51; at four visits a year state 
anxiety level was 47.00±2.35 (F=22.17; p=0.0000). 
 
At one visit a year trait anxiety level was 36.88±0.71; 
at two visits a year trait anxiety level was 
40.79±0.78; at three visits a year trait anxiety level 
was 49.35±0.54; at four visits a year trait anxiety 
level was 47.00±1.96 (F=37.69; p=0.0000). 
 
At one visit a year depression level was 40.63±0.59; 
at two visits a year depression level was 51.52±0.94; 
at three visits a year depression level was 62.14±0.94; 
at four visits a year depression level was 64.25±0.85 
(F=46.66; p=0.0000). 
 
According to One-Way ANOVA PSQI and 
depression have significant influence on hospital 
admissions. 
 
Patients with expressed dissomnic disorders in the 
anamnesis had one or two hospitalization a year, and 
patients with less expressed dissomnic disorders had 
no more than one hospitalization a year. 
 
If patients didn’t have hospitalization a year, PSQI 
was 6.5±0.27. If patients have one hospitalization a 
year, PSQI was 8.07±0.26. If patients have two 
hospitalizations a year, PSQI was 11.00±0.58. Only 1 
patient has three hospitalizations a year, his PSQI 
was 15 (F=17.79; p=0.0000). 
 
If patients didn’t have hospitalization a year, 
depression level was 47.92±1.03. If patients have one 
hospitalization a year, depression level was 
60.67±0.73. If patients have two hospitalizations a 
year, depression level was 68.63±0.33. Only 1 patient 
has three hospitalizations a year, his depression level 
was 69 (F=43.56; p=0.0000). 
 
It should be noted, state and trait anxiety have not 
significant influence on hospital admissions. 
According to One-Way ANOVA PSQI, state and trait 
anxiety have significant influence on stratification 
risk of complications. 
 
In patients of the general group PSQI, state and trait 
anxiety level significant differed depending on 
stratification risk of complications.  
 
At the 2nd stratification risk of complications PSQI 
was 4.90±0.21; at the 3rd stratification risk of 
complications PSQI was 6.51±0.97; at the 4th three 
stratification risk of complications PSQI was 
8.31±0.56 (F=37.88; p=0.0021). 
 
At the 2nd stratification risk of complications state 
anxiety level was 34.40±0.25; at the 3rd stratification 
risk of complications state anxiety level was 
38.75±0.60; at the 4th three stratification risk of 
complications state anxiety level was 47.27±0.64 
(F=39.65; p=0.0000). 
 
At the 2nd stratification risk of complications trait 
anxiety level was 34.60±0.25; at the 3rd stratification 
risk of complications trait anxiety level was 
39.05±0.58; at the 4th three stratification risk of 
complications trait anxiety level was 46.52±0.69 
(F=27.88; p=0.0000). 
 
It should be noted, depression has not significant 
influence on stratification risk of complications. 
Smoking is the main risk factor of cardiovascular 
pathology. According to One-Way ANOVA PSQI, 
state anxiety level and depression level have 
significant influence on smoking. 
 
In patients of the general group PSQI, state anxiety 
level and depression level significant differed 
depending on smoking. 
 
In non-smoking patients PSQI was 5.25±0.31, at 
refused smoking patients PSQI was 6.61±0.21, at 
smokers PSQI was 8.82±0.37 (F=21.58; p=0.0000). 
 
In non-smoking patients state anxiety level was 
37.12±0.97, at refused smoking patients state anxiety 
level 41.93±0.72, at smokers state anxiety level was 
49.26±0.26 (F=36.15; p=0.0000). 
 
In non-smoking patients depression level was 
40.63±0.59, at refused smoking patients depression 
level was 51.54±0.92, at smokers depression level 
was 62.63±0.83 (F=75.09; p=0.0000). 
 
It should be noted, trait anxiety level has not 
significant influence on smoking. The obtained 
significant data confirm patients with arterial 
hypertension use smoking as one of the easiest ways 
to reverse the psychoemotional stress. 
 
According to One-Way ANOVA state and trait 
anxiety level and depression level have significant 
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influence on regularity of hypotensive therapy 
 
State anxiety level was 41.49±0.82 in patients with 
arterial hypertension which are regularly taking the 
antihypertensive medicines; state anxiety level was 
49.25±0.49 in patients which did not take medicine 
(F=51.80; p=0.0000). 
 
Trait anxiety level was 40.69±0.72 in patients with 
arterial hypertension which are regularly taking the 
antihypertensive medicines; trait anxiety level was 
49.28±0.54 in patients which did not take medicine 
(F=75.67; p=0.0000). 
 
Depression level was 49.96±0.43 in patients with 
arterial hypertension which are regularly taking the 
antihypertensive medicines; depression level was 
63.14±0.79 in patients which did not take medicine 
(F=102.54; p=0.0000). 
 
The data of One-Way ANOVA confirmed the results 
of our research. The behavioral performances 
(smoking, irregularity of hypotensive therapy), 
dissomnic and psychosomatic disorders (high PSQI, 
high state and trait anxiety levels, high depression 
level), laboratory indicators (low urine melatonin 
level) have significant negative influence on the 
arterial hypertension clinical course (arterial 
hypertension degree, visits to the general practice 
doctor, hospital admissions, stratification risk of 
complications). 
 
Thus, psychosomatic ratios in patients with arterial 
hypertension are characterized by influence of 
psychological status on the arterial hypertension 
clinical course. Psychosomatic influences at arterial 
hypertension are characterized by increase of 
psychosocial disability and mixed anxiety-depressive 
disorders. 
 
Further, we carried out the One-Way ANOVA to 
assess the influence of sleep quality on social and 
demographic, behavioural, psychological, clinical, 
instrumental, and laboratory characteristics of 
patients with arterial hypertension. 
 
According to One-Way ANOVA sleep quality 
(dissomnic disorders) have significant negative 
influence on smoking status (a large number of 
smoking patients), a large number of visits to the 
general practice doctor and hospitalizations, 
irregularity of hypotensive therapy, periodically 
headaches, blood pressure variability, psychosomatic 
disorders (high state and trait anxiety levels, high 
depression level), low quality of life (low scales 
Physical Functioning (PF), General Health (GH), 
Vitality (VT), Role Emotional (RE), and Mental 
Health (MH). 
 
Also, we carried out the One-Way ANOVA to assess 
the influence of urine melatonin level on social and 
demographic, behavioural, psychological, clinical, 
instrumental, and laboratory characteristics of 
patients with arterial hypertension and dissomnic 
disorders. 
 
According to One-Way ANOVA low urine melatonin 
level has significant negative influence on elevated 
arterial hypertension degree, blood pressure 
variability, sleep quality (high PSQI), psychosomatic 
disorders (high state and trait anxiety levels, high 
depression level). 
 
Proceeding from results of our investigation we could 
allocate the most significant factors having an impact 
on the arterial hypertension clinical course and also 
define the significant factors having an impact on 
dissomnic disorders in patients with arterial 
hypertension. 
 
CONCLUSION: 
In conclusion, the patients with arterial hypertension 
have expressed dissomnic and psychosomatic 
disorders which have significant negative influence 
on the arterial hypertension clinical course and 
disease prognosis. Low urine melatonin level is 
associated with increased blood pressure, blood 
pressure variability, sleep disorders, psychosomatic 
disorders (high state and trait anxiety levels, high 
depression level), and low life quality of patients with 
arterial hypertension. Prescription of melatonin to the 
patients with arterial hypertension with sleep 
disorders is reasonable to correct dissomnic and 
psychosomatic disorders, clinical symptoms load of 
arterial hypertension, improvement of disease 
prognosis and life quality of patients with arterial 
hypertension. 
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